There has been a notable shift in interest for life-science companies over recent months from institutional investors investing through the public markets, but any plans to release further capital will rely on first-rate R&D.
Mark Howard
Advertisement
Mark Howard is a partner at Charles Russell LLP.
Articles by Mark Howard
Advertisement
Latest Updated Articles
The Importance of Continued Investment in R&DPublished: September 2nd 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
2
Standardizing Operations to Meet Global Sustainability and Resilience Goals
3
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
4
Takeda’s Sriman Banerjee Discusses Smart Packaging at CPHI Frankfurt 2025
5
